{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T11:40:13Z","timestamp":1786794013399,"version":"build-2736575974"},"reference-count":62,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["R01CA261937"],"award-info":[{"award-number":["R01CA261937"]}]},{"name":"NIH","award":["BLR&D I01BX005917"],"award-info":[{"award-number":["BLR&D I01BX005917"]}]},{"name":"NIH","award":["CSR&D I01CX002210"],"award-info":[{"award-number":["CSR&D I01CX002210"]}]},{"name":"NIH","award":["BLR&D IK6BX006041"],"award-info":[{"award-number":["BLR&D IK6BX006041"]}]},{"DOI":"10.13039\/100000738","name":"Department of Veterans Affairs","doi-asserted-by":"publisher","award":["R01CA261937"],"award-info":[{"award-number":["R01CA261937"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BLR&D I01BX005917"],"award-info":[{"award-number":["BLR&D I01BX005917"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"Department of Veterans Affairs","doi-asserted-by":"publisher","award":["CSR&D I01CX002210"],"award-info":[{"award-number":["CSR&D I01CX002210"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BLR&D IK6BX006041"],"award-info":[{"award-number":["BLR&D IK6BX006041"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Wisconsin Foundation","award":["R01CA261937"],"award-info":[{"award-number":["R01CA261937"]}]},{"name":"University of Wisconsin Foundation","award":["BLR&D I01BX005917"],"award-info":[{"award-number":["BLR&D I01BX005917"]}]},{"name":"University of Wisconsin Foundation","award":["CSR&D I01CX002210"],"award-info":[{"award-number":["CSR&D I01CX002210"]}]},{"name":"University of Wisconsin Foundation","award":["BLR&D IK6BX006041"],"award-info":[{"award-number":["BLR&D IK6BX006041"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Skin cancer remains a significant global health challenge, with rising incidence and associated mortality in late-stage and drug-resistant cases. This underscores a continuing need for more effective novel therapeutic options that can be utilized for efficient management of skin cancers. A promising approach involves exploiting novel targets, which are dysregulated in skin cancer, either alone or in combination with existing therapeutics. Among these, polo-like kinases (PLKs), a family of serine\/threonine kinases, has emerged as promising candidates due to their essential role in cell cycle and maintaining genomic stability, key hallmarks of cancer. Within this family, polo-like kinase 4 (PLK4) stands out as a structurally distinct member and the master regulator of centriole duplication, ensuring this process occurs only once per cell division. Dysregulation of PLK4 can disrupt genomic integrity, contributing to tumorigenesis, thus making it a promising target for cancer management. Notably, PLK4 is frequently overexpressed in several cancers, including skin cancer, and its precise role in skin cancer is an area of current investigation. Further, several small-molecule PLK4 inhibitors such as centrinone, YLZ-F5, CFI-400945, and RP-1664 have demonstrated efficacy in targeting PLK4. Among these, CFI-400945 has advanced to clinical trials, where it has shown modest anti-cancer activity. In this review, we provide a comprehensive overview of the known functions of PLK4 in skin cancer. Additionally, we discuss potential mechanistic insights into PLK4\u2032s involvement in skin cancer progression by extrapolating evidence from studies in other cancer types including colorectal cancer, thyroid cancer, lymphomas, leukemia, etc., while identifying gaps for future research.<\/jats:p>","DOI":"10.3390\/cells14171381","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T10:55:37Z","timestamp":1756983337000},"page":"1381","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Polo-like Kinase 4: A Molecular Culprit in Skin Cancer Pathogenesis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9241-4014","authenticated-orcid":false,"given":"Tanya","family":"Jaiswal","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Wisconsin, Madison, WI 53705, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8929-2972","authenticated-orcid":false,"given":"Durdana","family":"Muntaqua","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Wisconsin, Madison, WI 53705, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4239-9887","authenticated-orcid":false,"given":"Nihal","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Wisconsin, Madison, WI 53705, USA"},{"name":"William S. Middleton Memorial Veterans Hospital, Madison, WI 53705, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Zompit, M.D.M., and Stucki, M. (2021). Mechanisms of genome stability maintenance during cell division. DNA Repair, 108.","DOI":"10.1016\/j.dnarep.2021.103215"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.4161\/cc.10.14.16494","article-title":"From Plk1 to Plk5: Functional evolution of polo-like kinases","volume":"10","author":"Manning","year":"2011","journal-title":"Cell Cycle"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s00018-010-0279-9","article-title":"Polo-box domain: A versatile mediator of polo-like kinase function","volume":"67","author":"Park","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/j.str.2012.08.025","article-title":"The Structure of the Plk4 Cryptic Polo Box Reveals Two Tandem Polo Boxes Required for Centriole Duplication","volume":"20","author":"Slevin","year":"2012","journal-title":"Structure"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Lei, Q., Yu, Q., Yang, N., Xiao, Z., Song, C., Zhang, R., Yang, S., Liu, Z., and Deng, H. (2024). Therapeutic potential of targeting polo-like kinase 4. Eur. J. Med. Chem., 265.","DOI":"10.1016\/j.ejmech.2023.116115"},{"key":"ref_7","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00280-020-04098-w","article-title":"YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects","volume":"86","author":"Zhu","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"10631","DOI":"10.1021\/acs.jmedchem.5c00529","article-title":"Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 Inhibitor","volume":"68","author":"Bubenik","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9076","DOI":"10.1182\/blood-2022-158370","article-title":"Preliminary Results from a Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine or Decitabine in Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (TWT-202)","volume":"140","author":"Jonas","year":"2022","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/1541-7786.MCR-17-0197","article-title":"Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma","volume":"16","author":"Denu","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1620\/tjem.2023.J092","article-title":"Polo-Like Kinase 4 Correlates with Aggressive Tumor Characteristics, Shortened Disease-Free Survival and Overall Survival in Patients with Cutaneous Melanoma who Undergo Surgical Resection","volume":"262","author":"Zhang","year":"2024","journal-title":"Tohoku J. Exp. Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Coelho, P.A., Bury, L., Shahbazi, M.N., Liakath-Ali, K., Tate, P.H., Wormald, S., Hindley, C.J., Huch, M., Archer, J., and Skarnes, W.C. (2015). Over-expression of Plk4 induces centrosome amplification, loss of primary cilia and associated tissue hyperplasia in the mouse. Open Biol., 5.","DOI":"10.1098\/rsob.150209"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"E6311","DOI":"10.1073\/pnas.1518376112","article-title":"Epidermal development, growth control, and homeostasis in the face of centrosome amplification","volume":"112","author":"Kulukian","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","first-page":"100","article-title":"Transient PLK4 overexpression accelerates tumorigenesis in p53-deficient epidermis","volume":"18","author":"Larsimont","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"E6321","DOI":"10.1073\/pnas.1519388112","article-title":"Chronic centrosome amplification without tumorigenesis","volume":"112","author":"Vitre","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Jaiswal, T., Muntaqua, D., Chhabra, G., and Ahmad, N. (2025). Polo-like kinases and UV -induced skin car-cinogenesis: What we know and what\u2019s next. Photochem. Photobiol., Early View.","DOI":"10.1111\/php.70002"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Bandarian, F., Razi, F., Rezaei-Tavirani, M., Arjmand, B., Sherafat, S.J., and Nejad, M.R. (2024). Assessment of Recovery Time Effects on Human Primary Neonatal Dermal Fibroblasts After Exposure to Solar-Simulated Ultraviolet Radiation. J. Lasers Med. Sci., 15.","DOI":"10.34172\/jlms.2024.20"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ndiaye, M.A., Garvey, D.R., Chhabra, G., Singh, C.K., Nihal, M., and Ahmad, N. (2025). PLK4 is a potential therapeutic target in nonmelanoma skin cancers: Evidence from molecular and in vivo studies. Photochem. Photobiol., Early View.","DOI":"10.1111\/php.70006"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Jin, B., Zhang, Y., Miller, H.D., He, L., Ge, D., Wang, A.R., and You, Z. (2022). Defect of IL17 Signaling, but Not Centrinone, Inhibits the Development of Psoriasis and Skin Papilloma in Mouse Models. Biomedicines, 10.","DOI":"10.3390\/biomedicines10081976"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Huang, R., Liu, C., Fu, R., Yan, Y., Yang, J., Wang, X., and Li, Q. (2022). Downregulation of PLK4 expression induces apoptosis and G0\/G1-phase cell cycle arrest in keloid fibroblasts. Cell Prolif., 55.","DOI":"10.1111\/cpr.13271"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Zhang, X., Wei, C., Liang, H., and Han, L. (2021). Polo-Like Kinase 4\u2019s Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.587554"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2217\/bmm-2023-0565","article-title":"PLK4 Reflects Extrathyroidal Invasion, High Tumor Stage And Poor Prognosis in Papillary Thyroid Carcinoma Patients","volume":"18","author":"Hu","year":"2024","journal-title":"Biomarkers Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3892\/ijo.2018.4659","article-title":"High PLK4 expression promotes tumor progression and induces epithelial mesenchymal transition by regulating the Wnt\/\u03b2 catenin signaling pathway in colorectal cancer","volume":"54","author":"Liao","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1002\/2211-5463.13262","article-title":"Down-regulation of Polo-like kinase 4 (PLK4) induces G1 arrest via activation of the p38\/p53\/p21 signaling pathway in bladder cancer","volume":"11","author":"Yang","year":"2021","journal-title":"FEBS Open Bio"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wang, B., Zhang, X., Li, Z.-S., Wei, C., Yu, R.-Z., Du, X.-Z., He, Y.-J., Ren, Y., Zhen, Y.-W., and Han, L. (2024). Polo-like kinase 4 promotes tumorigenesis and glucose metabolism in glioma by activating AKT1 signaling. Cancer Lett., 585.","DOI":"10.1016\/j.canlet.2024.216665"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s11845-022-03007-9","article-title":"PLK4 inhibitor plus bortezomib exhibits a synergistic effect on treating multiple myeloma via inactivating PI3K\/AKT signaling","volume":"192","author":"Xu","year":"2022","journal-title":"Ir. J. Med. Sci. (1971)"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41419-021-03919-x","article-title":"Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma","volume":"12","author":"Zhao","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.32461","article-title":"Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity","volume":"77","author":"Chan","year":"2023","journal-title":"Hepatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s41419-018-1020-0","article-title":"MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR\/CHEK1 pathway","volume":"9","author":"Bao","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Lim, X., and Nusse, R. (2012). Wnt Signaling in Skin Development, Homeostasis, and Disease. Cold Spring Harb. Perspect. Biol., 5.","DOI":"10.1101\/cshperspect.a008029"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Di Bartolomeo, L., Vaccaro, F., Irrera, N., Borgia, F., Pomi, F.L., Squadrito, F., and Vaccaro, M. (2023). Wnt Signaling Pathways: From Inflammation to Non-Melanoma Skin Cancers. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021575"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Gajos-Michniewicz, A., and Czyz, M. (2020). WNT Signaling in Melanoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21144852"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Zhu, W., and Xie, B. (2023). PLK4 inhibitor exhibits antitumor effect and synergizes sorafenib via arresting cell cycle and inactivating Wnt\/\u03b2-catenin pathway in anaplastic thyroid cancer. Cancer Biol. Ther., 24.","DOI":"10.1080\/15384047.2023.2223383"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.taap.2006.12.006","article-title":"p53 and the pathogenesis of skin cancer","volume":"224","author":"Benjamin","year":"2007","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Loureiro, J.B., Raimundo, L., Calheiros, J., Carvalho, C., Barcherini, V., Lima, N.R., Gomes, C., Almeida, M.I., Alves, M.G., and Costa, J.L. (2021). Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance. Cancers, 13.","DOI":"10.3390\/cancers13071648"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/nar\/gkt849","article-title":"Polo-like kinase 4 transcription is activated via CRE and NRF1 elements, repressed by DREAM through CDE\/CHR sites and deregulated by HPV E7 protein","volume":"42","author":"Fischer","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Ward, A., Hudson, J.W., and Rotter, V. (2014). p53-Dependent and Cell Specific Epigenetic Regulation of the Polo-like kinases under Oxidative Stress. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087918"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1593\/neo.04325","article-title":"SAK, A New Polo-Like Kinase, Is Transcriptionally Repressed by p53 and Induces Apoptosis upon RNAi Silencing","volume":"7","author":"Li","year":"2005","journal-title":"Neoplasia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/PPO.0b013e31824d448c","article-title":"The Role of the PI3K-AKT Pathway in Melanoma","volume":"18","author":"Davies","year":"2012","journal-title":"Cancer J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41419-017-0088-2","article-title":"Polo-like kinase 4 mediates epithelial\u2013mesenchymal transition in neuroblastoma via PI3K\/Akt signaling pathway","volume":"9","author":"Tian","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Wang, B., Yu, R.-Z., Zhang, X.-Y., Ren, Y., Zhen, Y.-W., and Han, L. (2024). Polo-like kinase 4 accelerates glioma malignant progression and vasculogenic mimicry by phosphorylating EphA2. Cancer Lett., 611.","DOI":"10.1016\/j.canlet.2024.217397"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ajpath.2013.12.017","article-title":"Elevated YAP and its downstream targets CCN1 and CCN2 in basal cell carcinoma: Impact on keratinocyte pro-liferation and stromal cell activation","volume":"184","author":"Quan","year":"2014","journal-title":"Am. J. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jid.2016.02.005","article-title":"Yes-Associated Protein Contributes to the Development of Human Cutaneous Squamous Cell Carcinoma via Activation of RAS","volume":"136","author":"Jia","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1038\/s41388-020-1362-9","article-title":"The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis","volume":"39","author":"Zhang","year":"2020","journal-title":"Oncogene"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1101\/gad.1602907","article-title":"Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control","volume":"21","author":"Zhao","year":"2007","journal-title":"Genes Dev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.1111\/jcmm.15186","article-title":"A novel lncRNA PLK4 up-regulated by talazoparib represses hepatocellular carcinoma progression by promoting YAP-mediated cell senescence","volume":"24","author":"Jia","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Gan, Y., Li, X., Han, S., Liang, Q., Ma, X., Rong, P., Wang, W., and Li, W. (2022). The cGAS\/STING Pathway: A Novel Target for Cancer Therapy. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.795401"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1158\/2326-6066.CIR-19-0229","article-title":"STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity","volume":"7","author":"Falahat","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1182\/blood.2023019782","article-title":"Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML","volume":"142","author":"Man","year":"2023","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0898-6568(02)00080-3","article-title":"Involvement of NF-\u03baB signalling in skin physiology and disease","volume":"15","author":"Bell","year":"2003","journal-title":"Cell Signal."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"970","DOI":"10.15252\/emmm.201303541","article-title":"Epidermal p65\/NF-\u03baB signalling is essential for skin carcinogenesis","volume":"6","author":"Kim","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1038\/onc.2011.427","article-title":"NF-\u03baB inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the \u03b2-catenin pathway","volume":"31","author":"Thu","year":"2011","journal-title":"Oncogene"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.4161\/cc.26086","article-title":"NF\u03baB regulates expression of Polo-like kinase 4","volume":"12","author":"Ledoux","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/cam4.707","article-title":"Dermal fibroblasts induce cell cycle arrest and block epithelial\u2013mesenchymal transition to inhibit the early stage melanoma development","volume":"5","author":"Zhou","year":"2016","journal-title":"Cancer Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jid.2021.09.010","article-title":"Activation of Fibroblasts in Skin Cancer","volume":"142","author":"Hoste","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.canlet.2018.11.034","article-title":"PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma","volume":"443","author":"Zhang","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Biswas, H., Makinwa, Y., and Zou, Y. (2023). Novel Cellular Functions of ATR for Therapeutic Targeting: Embryogenesis to Tumorigenesis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241411684"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/j.celrep.2017.02.040","article-title":"ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment","volume":"18","author":"Chen","year":"2017","journal-title":"Cell Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/gcc.22115","article-title":"Upregulation of the ATR-CHEK1 pathway in oral squamous cell carcinomas","volume":"53","author":"Parikh","year":"2013","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Nakamura, T., Saito, H., and Takekawa, M. (2013). SAPK pathways and p53 cooperatively regulate PLK4 activity and centrosome integrity under stress. Nat. Commun., 4.","DOI":"10.1038\/ncomms2752"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1007\/s00432-019-02994-0","article-title":"PLK4: A promising target for cancer therapy","volume":"145","author":"Zhao","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/17\/1381\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:39:27Z","timestamp":1760035167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/17\/1381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":62,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["cells14171381"],"URL":"https:\/\/doi.org\/10.3390\/cells14171381","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]}}}